Clinical Trials Logo

Filter by:
NCT ID: NCT02679989 Completed - Obesity, Abdominal Clinical Trials

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity

Met-IER
Start date: February 2016
Phase: N/A
Study type: Interventional

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

NCT ID: NCT02679976 Completed - Visual Acuity Clinical Trials

Marketed Contact Lens Real World Through Focus Curve

Start date: July 2015
Phase: N/A
Study type: Interventional

This is a single-visit prospective study to establish a real world Marketed Contact Lens 'Through Focus Curve' (TFC) measurement by comparing the consistency of vision between myopes and hyperopes. 33 subjects will be enrolled (at least 15 myopes and 15 hyperopes), who are 40 years of age or older, for a 1-visit, 4-hour study for measurements to be taken.

NCT ID: NCT02679014 Completed - Celiac Disease Clinical Trials

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

Start date: March 6, 2016
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, two treatment, parallel group study to investigate the effects of RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease. Volunteers with previously diagnosed celiac disease will be randomized to receive either 100 milligrams (mg) RO5459072 or placebo twice daily with food for 28 days (Days 1 to 28).

NCT ID: NCT02678780 Completed - Clinical trials for Neuroendocrine Tumors

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

TALENT
Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).

NCT ID: NCT02678689 Completed - Batten Disease Clinical Trials

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Start date: February 2016
Phase: Phase 2
Study type: Interventional

This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.

NCT ID: NCT02678572 Completed - Melanoma, Ocular Clinical Trials

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

FOCUS
Start date: February 1, 2016
Phase: Phase 3
Study type: Interventional

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

NCT ID: NCT02678494 Completed - Neuropathic Pain Clinical Trials

Brain-Train Home Based Pain Treatment

Start date: June 9, 2016
Phase: N/A
Study type: Interventional

A study examining the effectiveness of neurofeedback therapy for the treatment of Central Neuropathic Pain (CNP), in patients with a Spinal Cord Injury, using a small user-friendly device which can be operated by patients at home.

NCT ID: NCT02678338 Completed - Clinical trials for Acute Myeloid Leukemia

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of anti-cluster of differentiation (CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies including acute myeloid leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory), or high risk myelodysplastic syndrome. Monoclonal antibodies, such as anti-CD47 monoclonal antibody Hu5F9-G4, block cancer growth in different ways by targeting certain cells.

NCT ID: NCT02677545 Completed - Clinical trials for Carotid Artery Stenosis

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

PRECISE-MRI
Start date: December 2016
Phase: Phase 2
Study type: Interventional

Patients with symptomatic or asymptomatic carotid stenosis in whom carotid artery stenting is planned are randomised between antiplatelet therapy with ticagrelor plus aspirin or clopidogrel plus aspirin and examined with brain MRI before and after stent treatment. The proportion of patients with new ischaemic lesions on MRI after treatment is compared between the two groups.

NCT ID: NCT02676947 Completed - Clinical trials for Pulmonary Arterial Hypertension

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

TRANSFORM-UK
Start date: January 2016
Phase: Phase 2
Study type: Interventional

An open label study to assess the safety and efficacy of tocilizumab in group 1 pulmonary arterial hypertension patients